scholarly journals Localized Tenosynovial Giant Cell Tumor: An Incidentally Found Lesion in the Shoulder

2021 ◽  
Vol 4 (2) ◽  
pp. 224-228
Author(s):  
Jorge Gomes Lopes ◽  
Manuel Gutierres ◽  
Luisa Vital ◽  
Miguel Relvas-Silva ◽  
Ricardo São-Simão ◽  
...  
Keyword(s):  
Giant Cell ◽  
Soft Tissues ◽  
Standard Treatment ◽  
Treatment Strategies ◽  
Case Series ◽  
Giant Cell Tumors ◽  
Tenosynovial Giant Cell Tumor ◽  
Complete Surgical Resection ◽  
Low Incidence ◽  
Specific Symptoms

The concept of localized and diffuse tenosynovial giant cell tumors (TSGCT) is recent and may still cause some confusion among surgeons. This disorder constitutes a family of proliferative lesions characterized by their origin in the articular synovium, tendon sheaths, or bursa. It is not always easy to diagnose this pathology, especially due to its multitude of presentation. We describe an incidentally found localized TSGCT intra-articularly located in the shoulder. The localized lesions are considered a more benign form that usually present not with specific symptoms but rather a manifestation of the disturbance in the affected joint or the surrounding soft tissues. MRI is indispensable for its diagnosis, and the standard treatment is complete surgical resection. Due to its low incidence, it is difficult to find literature that goes beyond clinical reports or small case series. With this report, we intend to call readers’ attention for the variable presentations, the different diagnostic and treatment strategies, and the expected outcomes.

Intramuscular Tenosynovial Giant Cell Tumor Harboring a Novel CSF1-CD96 Fusion Transcript

2021 ◽  
pp. 106689692110498
Author(s):  
Haider Mejbel ◽  
Gene P. Siegal ◽  
Shi Wei
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Gene Rearrangement ◽  
Fusion Transcript ◽  
Cell Tumor ◽  
Molecular Profile ◽  
Small Subset ◽  
Fusion Partner ◽  
Giant Cell Tumors ◽  
Tenosynovial Giant Cell Tumor

Tenosynovial giant cell tumors typically arise in the synovium of joints, bursae, or tendon sheaths. They may occur in an intra- or extra-articular location and can be divided into localized and diffuse types. The neoplastic nature of the lesion has been supported by a recurrent CSF1 gene rearrangement in a small subset of lesional cells, of which the most common fusion partner is COL6A3. Herein, we report a case of intramuscular localized tenosynovial giant cell tumor harboring a novel CSF1-CD96 fusion transcript, thus expanding the molecular profile of this tumor.

Case series study: the diagnosis and treatment of fifty tumors and pseudotumors at the proximal femur

MedPharmRes ◽  
2021 ◽  
Vol 6 (1) ◽  
pp. 40-46
Author(s):  
Ly Duc Minh Van ◽  
Thi Cao
Keyword(s):  
Giant Cell ◽  
Proximal Femur ◽  
Case Series ◽  
Clinical Findings ◽  
Functional Score ◽  
Giant Cell Tumors ◽  
Specific Tumor ◽  
Pathologic Fractures ◽  
Case Series Study ◽  
Fixation Devices

Introduction: Tumor and pseudotumor (TP) at the proximal femur (PF) can seriously affect mortality, extremity function, and body integrity. However, reports often focused on a specific tumor, not regional lesions. This study focuses on clinical findings, imaging, micro-pathology, and the treatment of all TP at the site. Methods: The study involved all patients who had a confirmed tumor or pseudotumor diagnosis at the PF. The clinical findings, X-ray, and biopsy were recorded and analyzed. Treatment was optional depending on the patient's situation and available condition of the hospital. The functional outcome, bone healing were defined at the last examination or two years of follow-up. Results: Fifty patients were involved in the study. Twenty-four patients had apparent tumors. TP at the PF, neck-trochanter, trochanters, and neck were 21 (42%), 16 (32%), 9 (18%), and 4 (8%) cases, respectively. There were 29 (58%) pathologic fractures. Biopsy was made for all patients. Twenty-three cases (46%) were malignant, and 8 (16%) cases were giant cell tumors. Thirtythree patients suffered from an operation. Ennerking's functional score was excellent, good, fair, and poor in 24 (48%), 5 (10%), 1 (2%), and 20 (40%) patients, respectively. For the last outcomes of 33 operated patients, 17 healed, three unchanged, one worse, and two dead. Conclusions: For the PF TP, the rate of malignant and pathological fracture was high. The giant cell tumor was not rare. The resection of the TP combined with grafts using ordinary fixation devices was satisfactory.

Surgical strategy for the management of sacral giant cell tumors: a 32-case series

2012 ◽  
Vol 12 (6) ◽  
pp. 484-491 ◽  
Author(s):  
Guodong Li ◽  
Dong Fu ◽  
Kai Chen ◽  
Xiaojun Ma ◽  
Mengxiong Sun ◽  
...  
Keyword(s):  
Giant Cell ◽  
Case Series ◽  
Surgical Strategy ◽  
Giant Cell Tumors

Giant Cell Tumors of the Skull Base: Case Series and Current Concepts

2013 ◽  
Vol 19 (1) ◽  
pp. 12-21 ◽  
Author(s):  
Sampath Chandra Prasad ◽  
Enrico Piccirillo ◽  
Amjad Nuseir ◽  
Giuliano Sequino ◽  
Giuseppe De Donato ◽  
...  
Keyword(s):  
Skull Base ◽  
Giant Cell ◽  
Case Series ◽  
Base Case ◽  
Giant Cell Tumors

scholarly journals Primary Ewing's Sarcoma of the Spine: Four Case Report

KYAMC Journal ◽  
2019 ◽  
Vol 10 (3) ◽  
pp. 164-167
Author(s):  
Md Mofazzal Sharif ◽  
Khaleda Parvin ◽  
Umme Iffat Siddiqua ◽  
A.Q. Mehedi Hassan ◽  
Jabed Hossain ◽  
...  
Keyword(s):  
Soft Tissues ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Correct Diagnosis ◽  
Surgical Excision ◽  
Cord Compression ◽  
Acute Paraplegia ◽  
Low Incidence ◽  
Specific Symptoms ◽  
Common Malignancy

Ewing's sarcoma is a common malignancy of the bone and soft tissues in pediatric patients. It mostly affects the long bones and pelvis, and less commonly the flat bones and vertebrae. Primary Ewing's sarcoma affecting the spine is very rare. The patient has non-specific symptoms for a prolonged period of time before the correct diagnosis is given. Patients can present with acute paraplegia due to spinal cord compression, which needs prompt surgical intervention. Early diagnosis and treatment are important for neurological recovery. The definitive management includes three main modalities: surgery, radiotherapy and combination chemotherapy. Adequate surgical excision may not be feasible because of anatomical limitations and local control is mainly achieved by radiotherapy. Because of the low incidence of these tumors, a multitude of therapeutic strategies have been employed with varying success. Currently there are no clinical guidelines outlining optimal management KYAMC Journal Vol. 10, No.-3, October 2019, Page 164-167

scholarly journals Management of a Huge Tenosynovial Giant Cell Tumor of the Wrist

2021 ◽  
Author(s):  
Woo Jong Kim ◽  
Sang Mi Lee ◽  
Byungsung Kim ◽  
Jae-Hwi Nho ◽  
Jun Bum Kim ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Rare Case ◽  
Tendon Sheath ◽  
Cell Tumor ◽  
Benign Neoplasms ◽  
Diffuse Type ◽  
Giant Cell Tumors ◽  
Tenosynovial Giant Cell Tumor

Tenosynovial giant cell tumors (TGCTs) are typically benign neoplasms of the joint, bursa, and tendon sheath. Usually, TGCT presents as a small localized tumor on the hand and wrist. The diffuse-type TGCT is more aggressive and mainly affects large joints such as knees, hips, ankles, and elbows. Diffuse-type TGCT of small joints is rare. To our knowledge, this is a very rare case of a huge diffuse-type TGCT on the wrist. We report a huge TGCT, which grew gradually over 10 years.

Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidar-tinib: A Review

2020 ◽  
Vol 20 ◽  
Author(s):  
Yunes M.M.A. Alsayadi ◽  
Pooja A. Chawla
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Pigmented Villonodular Synovitis ◽  
Cell Tumor ◽  
Drug Candidate ◽  
Brand Name ◽  
Giant Cell Tumors ◽  
Tenosynovial Giant Cell Tumor ◽  
Pigmented Villonodular ◽  
Stimulating Factor

Background: Tenosynovial giant cell tumor refers to a group of rarely occurring tumors that are formed in the joints, which are characterized by pain, swelling, and limitation of movement of the joint. Surgery is the main treatment strategy, but the tumor is likely to recur, especially in pigmented villonodular synovitis, which is the diffuse-type of giant cell tumor. Pexidartinib was approved in August 2019 by the Food and Drug Administration (FDA) with a brand name TURALIO as the first systemic approved therapy for patients having Tenosynovial Giant Cell Tumors (TGCT). Objective: In this review, different aspects pertaining to pexidartinib have been summarized including pathophysiology of TGCT, chemistry, pharmacokinetics and pharmacodynamics of pexidartinib. Special attention is given to various reported clinical trials of pexidartinib. Methods: A comprehensive literature search was conducted in the relevant databases to identify studies published in this field during recent years Conclusion: Pexidartinib acts by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway which leads to inhibition of the cell lines proliferation and promotes the autophosphorylation process of ligand-induced CSF1 receptor. Pexidartinib emerged as a potential drug candidate for the treatment of TGCT.

Sign in / Sign up

Export Citation Format

Share Document